Evergreen Capital Management LLC Increases Holdings in AbbVie Inc. (NYSE:ABBV)

Evergreen Capital Management LLC grew its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 3.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,612 shares of the company's stock after purchasing an additional 2,099 shares during the period. Evergreen Capital Management LLC's holdings in AbbVie were worth $10,238,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of ABBV. Fiduciary Advisors Inc. purchased a new position in AbbVie during the fourth quarter worth approximately $29,000. EnRich Financial Partners LLC raised its stake in shares of AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after buying an additional 110 shares during the period. Promus Capital LLC purchased a new position in shares of AbbVie during the 4th quarter valued at approximately $30,000. Bradley & Co. Private Wealth Management LLC acquired a new stake in AbbVie in the 4th quarter valued at $31,000. Finally, Prudent Man Investment Management Inc. purchased a new stake in AbbVie in the 4th quarter worth $32,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Trading Up 0.6 %

NYSE ABBV traded up $1.10 during trading hours on Friday, reaching $172.78. The company had a trading volume of 8,474,425 shares, compared to its average volume of 6,005,419. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The stock has a market capitalization of $305.64 billion, a P/E ratio of 71.99, a price-to-earnings-growth ratio of 1.62 and a beta of 0.55. The stock has a 50-day moving average of $198.47 and a 200 day moving average of $187.71. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter last year, the business earned $2.79 earnings per share. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $1.64 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.80%. AbbVie's dividend payout ratio is presently 273.33%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Citigroup increased their price objective on shares of AbbVie from $205.00 to $215.00 and gave the company a "buy" rating in a report on Monday, February 3rd. UBS Group raised their price target on shares of AbbVie from $181.00 to $190.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd. Guggenheim reiterated a "buy" rating and set a $214.00 price objective on shares of AbbVie in a research note on Thursday. Erste Group Bank raised AbbVie to a "strong-buy" rating in a report on Monday, March 17th. Finally, StockNews.com lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, April 9th. Seven equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $210.71.

Insider Buying and Selling

In other AbbVie news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the sale, the executive vice president now directly owns 53,234 shares in the company, valued at $11,183,398.72. This represents a 52.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Perry C. Siatis sold 5,778 shares of the business's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the completion of the transaction, the executive vice president now owns 22,381 shares of the company's stock, valued at approximately $4,429,199.90. This trade represents a 20.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,471 shares of company stock valued at $23,426,451. Corporate insiders own 0.25% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.